Home › Sosei Subsidiary Heptares Enters Strategic Drug Discovery Collaboration With Pfizer Inc. Focused On GPCR Targets Across Multiple Therapeutic Areas
 

Keywords :   


Sosei Subsidiary Heptares Enters Strategic Drug Discovery Collaboration With Pfizer Inc. Focused On GPCR Targets Across Multiple Therapeutic Areas

2015-12-02 01:37:23| drugdiscoveryonline Home Page

Sosei Group Corporation (“Sosei”) recently announces that its wholly-owned subsidiary, Heptares Therapeutics has entered into a strategic drug discovery collaboration with Pfizer Inc. to research and develop potential new medicines directed at up to 10 G protein-coupled receptor (GPCR) targets across multiple therapeutic areas

Tags: areas multiple drug focused

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
08.05US revokes licences for sales of chips to Huawei
08.05Prime Packaging invests in Nilpeter FA-26 flexo press
08.05MCC Drogheda honored at Irish Print Awards
08.05First Quarter 2024 HighlightsIts a Margin Story for Solid Waste
08.05McNeilus Showcases Purpose-Built Trucks, Advanced Technology and Industry Expertise at Waste Expo
08.05New Way to Showcase Innovation and Industry Partnership at Waste Expo
08.05NWRA Hosts Chairmans Reception at WasteExpo 2024
08.05CCU and Titus Celebrate Construction of Recycling Facility in South America
More »